GlobeNewsWire
15 May 2026, 20:05 UTC · 26w ago
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
Verdict
Headline takes no side. We score CADL +1.00 across three claims — strongly bullish.
- Expected · CADL
+1.00strongly bullish
−1 bearish0bullish +1More positive than 99% of ticker scores this week





